Molecular/Genetic Therapies in Ovarian Cancer: Future Opportunities and ChallengesZIEBARTH, ANGELA J. MD; LANDEN, CHARLES N. Jr MD; ALVAREZ, RONALD D. MDClinical Obstetrics and Gynecology: March 2012 - Volume 55 - Issue 1 - p 156–172 doi: 10.1097/GRF.0b013e31824b1699 Ovarian Cancer Abstract Author Information Ovarian cancer is the most lethal gynecologic cancer. Traditional therapies have included surgical management and cytotoxic chemotherapy; however, treatment paradigms continue to shift from empiric cytotoxic chemotherapy to more individualized treatment. Recent research efforts have focused on determining and targeting the molecular biological mechanisms of ovarian cancer in an attempt to develop novel therapeutic modalities with the ultimate goal of improving outcome while limiting toxicity. This chapter reviews progress in the development of novel therapies directed at major pathways implicated in ovarian tumorigenesis including angiogenesis, PARP inhibition, signal transduction, antifolate therapies, death receptor-mediated therapies, histone deacetylase inhibition, immunotherapeutics, and oncolytics. The Division of Gynecologic Oncology, The University of Alabama at Birmingham, Birmingham, Albama R.D.A. does have associations he would like to disclose as follows: Ad board for Genentech and Esai/Morphotec and research support from Morphotec, Pfizer, Genentech, Merrimack, and Tracon. The other authors declare that they have nothing to disclose. Correspondence: Ronald D. Alvarez, MD, Division of Gynecologic Oncology, University of Alabama at Birmingham, 176F Rm 10250, Birmingham, AL 35249. E-mail: firstname.lastname@example.org © 2012 Lippincott Williams & Wilkins, Inc.